newsfilter
← Latest News
GlobeNewswire·

Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202

-- BMB-202 is a highly selective 5-HT2A agonist that exhibits a more than 30-fold selectivity over 5-HT2C and more than 500-fold selectivity over 5-HT2B -- -- BMB-202 is the first clinical candidate from an extensive